Tests brimonidine eye drops for redness in glaucoma patients
Tests brimonidine eye drops in adults with glaucoma using netarsudil and latanoprost drops.
Plain-language title generated from the registry record
Registry title: Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
Key facts
- Where
- Kansas City, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07209410, who can take part
Where in United States
- Vision SourceKansas City, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
- Trial code
- NCT07209410
- Record updated
- 18 November 2025
- Original description
To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering.Read full original descriptionShow less
Impact of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering.
Inclusion: 1. Adult patients 18-65 years old diagnosed with open-angle glaucoma or ocular hypertension; Currently on netarsudil 0.02%/latanoprost 0.005% monotherapy for a minimum of 2-6 weeks; Able to move from current topical glaucoma treatment to netarsudil 0.02%/latanoprost 0.005% for a minimum of 4 weeks or longer based on FDA recommended washout per drug classification prior to Visit 3; Experience conjunctival redness as graded on the Efron scale of at least grade 2 after minimum of 4 weeks on netarsudil 0.02%/latanoprost 0.005% mono-therapy or longer based on recommended washout per drug classification 4. Have a best corrected Visual Acuity by Snellen chart of 20/30 or better in study eye; Are willing and able to self-administer or have an able person available to assist with administration of study drug; Willing and able to comply with study procedures and attend follow-up visits.
Exclusion: Use of any other topical ocular medications; Concurrent or past use in the last 90 days of vasoconstrictive ocular drops other than brimondine 0.025%; Have undergone previous incision IOP lowering surgeries; Have had intraocular or per-ocular surgery within the past 3 months; Advanced glaucoma or c/d ratio greater than 0.8. Are non-responsive to topical treatment with netarsudil 0.02%/latanoprost 0.005%; In the judgement of the investigator, have previous or currently active clinically significant systemic or ocular disease in either eye that could affect study outcomes; Allergy or hypersensitivity to brimonidine or other components of brimonidine tartrate 0.025% or netarsudil 0.02%/latanoprost 0.005%; Active ocular infection, inflammation unrelated to glaucoma therapy, uveitis, iritis or congenital aphakia; Have pterygium/pinguecula, chemosis, episcleritis, scleritis (or any condition that may affect hyperemia grading) in the opinion of the investigator; Have undergone previous laser surgery for glaucoma (selective laser trabeculoplasty (SLT) or argon laser trabeculoplasty (ALT)), or microinvasive glaucoma surgery (MIGS) with 6 months of screening; Have moderate or severe dry eyes; Pregnant, plan to become pregnant or breastfeeding.